Loading
Life sciences · Journal article
Pharmacological Research · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Type 2 diabetes (T2D) and cancer frequently coexist and are connected by hyperinsulinemia, hyperglycemia, obesity, chronic inflammation, and multiorgan metabolic dysfunction. These alterations activate insulin/insulin-like growth factor 1, PI3K/AKT/mTOR, MAPK, JAK/STAT, and NF-κB signaling while reshaping the tumor microenvironment through endocrine, immune, and metabolic pathways. This review synthesizes epidemiological and mechanistic evidence linking T2D with cancer and evaluates the oncological implications of major antidiabetic therapies. We discuss how dysfunction of skeletal muscle, adipose tissue, liver, pancreas, and hormonal axes may converge on tumor growth, immune evasion, and treatment resistance. We then critically examine metformin, insulin analogs, sulfonylureas, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and dual GIP/GLP-1 receptor agonists. Metformin has demonstrated extensive preclinical antitumor activity, whereas randomized clinical studies have generally yielded neutral cancer-specific outcomes. Human findings for other agents vary according to cancer type, metabolic phenotype, treatment duration, and study design, with observational estimates particularly sensitive to diabetes severity, obesity, treatment selection, and reverse causality. In clinical practice, glucose-lowering therapy is therefore best guided by glycemic efficacy, cardiovascular and renal protection, body-weight effects, safety, cancer-treatment context, and prognosis. Integrating pharmacological mechanisms with clinically achievable exposure and human outcome data may enable more precise metabolic management at the diabetes-cancer interface.